DoD Multiple Scherosis Exploration-Hypothesis Development Award

The summary for the DoD Multiple Scherosis Exploration-Hypothesis Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Multiple Scherosis Exploration-Hypothesis Development Award: The MSRP EHDA mechanism is being offered for the first time in FY16.
The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required.
The proposed research project should be innovative, feasible, and supported by strong rationale. Innovative research may introduce a novel paradigm, challenge existing paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of MS.
Note for projects involving animal models of MS: Applicants should be prudent in the choice of animal model(s) for their proposed research. While studies of MS symptoms have relied on various animal models of demyelination or specific genetic alterations, it is not always clear that the underlying mechanisms in these models are relevant to human MS, in terms of specific human symptoms. Applicants must justify the relevance of their proposed animal model(s) to the specific human MS symptoms to be studied.
Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm. PIs seeking funding for clinical trials relevant to MS Symptoms should refer to the FY16 MSRP Pilot Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-16-MSRP-PCTA).